Philipp W. Raess

Philipp W. Raess

Auto-generated profile, based on publicly available information

Philipp W. Raess

Department of Pathology and Laboratory Oregon Health & Science University Portland Oregon USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SCSusanne M Clee
Susanne M Clee
BYBrian S Yandell
Brian S Yandell
KSKathryn M Schueler
Kathryn M Schueler
MRMary E Rabaglia
Mary E Rabaglia
OROliver C Richards
Oliver C Richards
AAAlan D Attie
Alan D Attie

9 June 2010 in Endocrinology
Verified
Journal Article
Open access
PDF file
JLJeremy A. Lavine
Jeremy A. Lavine
PRPhilipp W. Raess
Philipp W. Raess
DSDonald S. Stapleton
Donald S. Stapleton
MRMary E. Rabaglia
Mary E. Rabaglia
JSJoshua I. Suhonen
Joshua I. Suhonen
AAAlan D. Attie
Alan D. Attie
An absolute or functional deficit in β-cell mass is a key factor in the pathogenesis of diabetes. We model obesity-driven β-cell mass expansion by studying the diabetes-resistant C57BL/6-Leptinob/ob mouse. We previously reported that cholecystokinin (Cck) was the most up-regulated gene in obese pancreatic islets. We now show that islet cholecystokinin (CCK) is up-regulated 500-fold by obesity and expressed in both α- and β-cells. We bred a null Cck allele into the C57BL/6-Leptinob/ob background and investigated β-cell mass and metabolic parameters of Cck-deficient obese mice. Loss of CCK resulted in decreased islet size and reduced β-cell mass through increased β-cell death. CCK deficiency and decreased β-cell mass exacerbated fasting hyperglycemia and reduced hyperinsulinemia. We further investigated whether CCK can directly affect β-cell death in cell culture and isolated islets. CCK was able to directly reduce cytokine- and endoplasmic reticulum stress-induced cell death. In summary, CCK is up-regulated by islet cells during obesity and functions as a paracrine or autocrine factor to increase β-cell survival and expand β-cell mass to compensate for obesity-induced insulin resistance.

2 February 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SNSarah J Nagle
Sarah J Nagle
CMCatherine Murphree
Catherine Murphree
PRPhilipp W Raess
Philipp W Raess
LSLevanto Schachter
Levanto Schachter
ACA I Chen
A I Chen
RMRichard T Maziarz
Richard T Maziarz

30 May 2019 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JDJennifer B. Dunlap
Jennifer B. Dunlap
JLJessica Leonard
Jessica Leonard
MRMara Rosenberg
Mara Rosenberg
RCRachel Cook
Rachel Cook
RPRichard Press
Richard Press
ETElie Traer
Elie Traer
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a clinical course predicted by recurrent cytogenetic abnormalities and/or gene mutations. The NPM1 insertion mutations define the largest distinct genetic subset, ∼30% of AML, and is considered a favorable risk marker if there is no (or low allelic ratio) FLT3 internal tandem duplication (FLT3 ITD) mutation. However, ∼40% of patients with mutated NPM1 without FLT3 ITD still relapse, and the factors that drive relapse are still not fully understood. We used a next‐generation sequencing panel to examine mutations at diagnosis; clearance of mutations after therapy, and gain/loss of mutations at relapse to prioritize mutations that contribute to relapse. Triple mutation of NPM1, DNMT3A and IDH1/2 showed a trend towards inferior overall survival in our discovery dataset, and was significantly associated with reduced OS in a large independent validation cohort. Analysis of relative variant allele frequencies suggests that early mutation and expansion of DNMT3A and IDH1/2 prior to acquisition of NPM1 mutation leads to increased risk of relapse. This subset of patients may benefit from allogeneic stem cell transplant or clinical trials with IDH inhibitors.

1 September 2015 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
PRPhilipp W. Raess
Philipp W. Raess
MBMarilyn Baird-Howell
Marilyn Baird-Howell
RARajesh Aggarwal
Rajesh Aggarwal
NWNoel N. Williams
Noel N. Williams
EFEmma E. Furth
Emma E. Furth

20 December 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CACatalina Amador
Catalina Amador
ABAlyssa Bouska
Alyssa Bouska
GWGeorge Wright
George Wright
DWDennis D. Weisenburger
Dennis D. Weisenburger
AFAndrew L. Feldman
Andrew L. Feldman
JIJaveed Iqbal
Javeed Iqbal
PURPOSE: Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS: We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS: In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION: We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.